TL;DR
Longevity medicine is a clinical specialty that uses biological-age measurement, multi-omics data, and continuous monitoring to extend healthspan, not just lifespan. The field has its own peer-reviewed definition, its own physician credentials, and as of 2024, its first government-licensed clinical framework.
- The 2021 Lancet Healthy Longevity definition anchors it as “advanced personalised preventive medicine powered by deep biomarkers of aging and longevity”
- The global healthspan-lifespan gap reached 9.6 years in 2019, as per 2024 JAMA Network Open analysis of 183 WHO member states
- More than 700 dedicated longevity clinics operate globally as of April 2026, with the market forecast to reach $33.4B by 2034
- It is not cosmetic anti-aging, biohacking, or concierge primary care, even where delivery models overlap
- Practitioners come from internal medicine, endocrinology, and lifestyle medicine, credentialed through A4M, HLMS, and emerging regulatory bodies.
The average person worldwide spends nearly a decade in a measurable disease burden before death. That gap, 9.6 years between life expectancy and healthy life expectancy according to a 2024 JAMA Network Open analysis, is what longevity medicine was built to compress.
The market is responding.
The global longevity clinic services market reached $11.08 billion in 2025, with more than 700 dedicated longevity clinics now operating worldwide. The count is forecast to triple over the next decade.
But the category is forming faster than its public definition. Most people searching for longevity medicine today pull answers from clinic homepages, supplement brands, and biohacking influencers who use the same words to describe very different things. The field has a peer-reviewed clinical definition, an emerging set of physician credentials, and as of 2024, its first government-licensed clinical framework. None of these are well-known outside the field.
What longevity medicine actually is
The clearest definition comes from The Lancet Healthy Longevity, which describes the field as “advanced personalised preventive medicine powered by deep biomarkers of aging and longevity.” That single sentence does more work than most marketing pages built around it.
Three elements matter in the definition.
- “Preventive” means the work happens before disease presents, not after.
- “Personalised” means the unit of care is the individual, with their own biology, history, and lifestyle.
- “Deep biomarkers of aging” means measurement goes beyond the standard sick-care panel and into biological age, multi-omics, and longitudinal physiological signals.
The reason this field exists at all is the gap between how long people live and how long they live well. The Mayo Clinic analysis behind that 9.6-year figure found that the gap widened by 13% across 183 WHO member states between 2000 and 2019. The average person now spends nearly a decade in a measurable disease burden before death.
The gap is not abstract for the people building tools to close it.
“My family has had a lot of health issues. And it became my passion to use my talent in technology to support healthy longevity worldwide, helping people live healthier, longer and better lives.”
—Samir Mitra, Founder and CEO, Reya.ai. (Source: Longevity.Technology interview, November 2025.)
Traditional preventive medicine, as practiced in most primary care settings, mostly screens for the diseases people are about to get. Longevity medicine is structured around the biology underneath those diseases.
The hallmarks of aging, defined in Cell in 2023, expanded the original nine hallmarks to twelve, adding chronic inflammation, gut dysbiosis, and disabled macroautophagy. Each hallmark is a measurable mechanism, not a diagnosis. The shift in framing matters.
A clinician operating in longevity medicine asks which mechanisms are accelerating in this specific patient, not whether those mechanisms have produced a disease code yet.
“Clinical-grade tools” in this context means something specific. It refers to validated biological age clocks like GrimAge and DunedinPACE, multi-omics panels integrating genomic, proteomic, metabolomic, and microbiome data, cardiopulmonary fitness measurement via VO₂ max, body composition via DEXA, advanced cardiovascular markers like ApoB and Lp(a), and continuous physiological data from wearables. These are different from the consumer-grade tests and supplement protocols that sometimes get marketed under the same label.
Longevity medicine vs traditional primary care
| Traditional primary care | Longevity medicine |
| Reactive. Visit triggered by symptom or annual check | Proactive. Visit triggered by longitudinal monitoring |
| Standard lab panel (CBC, lipid panel, basic metabolic) | Biological age, multi-omics, advanced cardiovascular markers |
| Diagnoses disease | Tracks biology before disease |
| 15 to 30 minute episodic visit | 60 to 180 minute visit, continuous coordination between visits |
| Mostly insurance-billable | Mostly out-of-pocket or membership-based |
| Population-average reference ranges | Individual longitudinal baseline |
| One-size-fits-all preventive guidelines | Personalised protocol based on individual biomarker profile |
What longevity medicine is not
The fastest way to get clarity on a new clinical category is to map what it is not. Three categories get conflated with longevity medicine often enough that the conflation has become its own problem.
It is not cosmetic anti-aging
The global anti-aging products market reached $55.66 billion in 2025, dominated by topical skincare, anti-wrinkle products, and aesthetic procedures. That market sits in a different clinical conversation entirely. Cosmetic anti-aging targets the visible signs of aging. Longevity medicine targets the biological mechanisms of aging. One is dermatology and aesthetics. The other is internal medicine, endocrinology, geroscience, and preventive cardiology, organised around biomarker-driven protocols.
Conflating the two is a clinical error, not a labeling error. A patient who walks into a cosmetic anti-aging practice expecting to have their cardiovascular risk profile, biological age, and metabolic health assessed will leave with a serum bottle. The reverse is also true. A practice marketing itself with cosmetic vocabulary attracts patients who are not looking for longevity care, then has to either reframe the engagement or deliver something narrower than the discipline allows.
It is not biohacking
Self-experimentation is its own category. The most visible example is Bryan Johnson, whose Blueprint protocol publishes hundreds of biomarkers, supplement regimens, and intervention experiments openly on the internet. Whatever the merits of any particular Johnson experiment, it is one person testing protocols on himself with a team that supports him. That is not the same as a credentialed physician running a longitudinal protocol on a patient with informed consent, standard-of-care safeguards, and proper diagnostic workups.
Self-directed biohacking is a public experiment of one. Longevity medicine vs traditional medicine differs in scope, but it shares with traditional medicine the same basic premise. A licensed clinician is responsible for the patient. That responsibility includes not running interventions that have not cleared validation, even when the patient asks for them.
It is not concierge primary care
Concierge medicine charges a membership fee for better access, longer appointments, and more direct communication with a physician. The clinical content of concierge primary care is the same as standard primary care, mostly. The difference is the delivery model.
Longevity clinics often look similar from the outside. Membership-based. Long visits. Direct physician access. The clinical content differs. A longevity clinic is structured around biological age measurement, multi-omics workups, and continuous data integration as default workflow, not as upgrades.
The clinical question is different. A concierge practice asks how to deliver better reactive care. A longevity practice asks how to detect and intervene on aging biology before it produces disease.
The operational engine of longevity medicine
The framework that organizes modern longevity work requires a definitive bridge between complex systems biology data and everyday human habits. At its architectural foundation, longevity medicine is powered by the P4 medicine framework (Predictive, Preventive, Personalized, Participatory) pioneered by systems biologist Leroy Hood. This framework describes how automated care is executed, utilizing continuous longitudinal tracking to forecast metabolic or biological risk cycles years before physical symptoms manifest.
However, continuous data tracking without an actionable behavioral mechanism is just digital noise. This is the precise bottleneck where data systems must connect with proven, evidence-based lifestyle medicine.
Reya organizes its comprehensive clinical software platform explicitly around the 6 Pillars of Lifestyle Medicine:
- Nutrition
- Physical Activity
- Stress Management
- Restorative Sleep
- Social Connection
- Toxic Substance Avoidance
What changed fundamentally between basic wellness trends and 2026 is that the digital infrastructure to deliver these six core pillars at an institutional scale finally exists.
Reya uses P4 systems architecture to transition these pillars from generalized advice into hyper-personalized, data-driven daily protocols. The platform captures deep biomarker realities first, then dynamically deploys lifestyle interventions to systematically shift biological age indicators.
Who is qualified to practice longevity medicine
This is the part of the field with the most public confusion. Longevity medicine is not yet a board-recognised specialty under the American Board of Medical Specialties, which oversees the 24 formal physician specialties in the United States. That sentence does not mean unqualified people are practicing. It means credentialing is consolidating across several routes, none of which are yet harmonised.
The longest-running route is the American Board of Anti-Aging and Regenerative Medicine, or ABAARM, administered by the American Academy of Anti-Aging Medicine (A4M) since the 1990s.
ABAARM certification is open to MDs and DOs and requires three parts: a written exam, an oral exam, and a documentation submission. A4M also runs a Fellowship in Longevity Medicine, a five-module curriculum physicians complete after ABAARM and ABAAHP testing. The post-nominal FAARM signals completion of the Fellowship in Anti-Aging, Regenerative and Functional Medicine.
A second route is forming through the Healthy Longevity Medicine Society. HLMS was founded in August 2022 as a non-profit international body explicitly working to establish longevity medicine as an independent recognised specialty. Evelyne Bischof, lead author of the 2021 Lancet definition paper, was appointed president in 2025. The society is developing physician guidelines, professional standards, and a coordinated clinical research agenda.
The clinical training programs themselves are growing. Bischof and Alex Zhavoronkov co-developed Longevity Medicine 101, a CME-accredited course launched in August 2021, and Longevity Medicine 201, a 200-slide curriculum covering deep aging clocks, geroscience, and clinical application. Both are accessible to physicians globally.
What does a longevity doctor do once trained?
They order, interpret, and act on biomarker data most primary care physicians do not see, biological age, multi-omics panels, advanced cardiovascular markers, body composition, and continuous wearable data. They design longitudinal protocols around the hallmarks of aging rather than around presenting symptoms. The longevity specialty is defined as much by what is measured as by who measures it.
A trained longevity physician is also equipped to coordinate across nutrition, exercise physiology, sleep medicine, and behavioral coaching as part of a single protocol, which is why most serious longevity clinics operate with multidisciplinary teams rather than solo practitioners.
Where longevity medicine is available
Three delivery models cover most of the field globally.
Standalone longevity clinics are the largest and fastest-growing category. They are typically private, membership-based, and built from the ground up around biomarker-driven protocols. North America held roughly 38.5 percent of longevity clinic revenue in 2025. Major Western clinics include Fountain Life, Cenegenics, and Human Longevity Inc. in the United States, Clinique La Prairie and Chenot in Europe, and Longevity Center Switzerland.
Integrative and functional medicine practices form the second category. The overlap with longevity medicine is real, particularly in lifestyle-driven protocols and supplement use. The distinction is the diagnostic framework. Functional medicine is built around root-cause analysis of chronic illness in symptomatic patients. Longevity medicine is built around aging biology in asymptomatic ones. Many practices straddle both. The boundary is more about clinical orientation than a hard line.
The third category is executive health programs inside hospital systems. Mayo Clinic Executive Health, Cleveland Clinic Executive Health, and Johns Hopkins Executive Health are the widely known US examples. These programs traditionally focused on comprehensive annual screenings for senior leaders. Several are now integrating longevity-specific testing and protocols, which makes them a hybrid category.
Geographically, the field is no longer concentrated in the United States and Europe. Asia-Pacific is forecast to grow at roughly 10.35 percent CAGR through 2031. Singapore’s National University Health System opened the world’s first public-hospital Healthy Longevity Clinic at Alexandra Hospital in August 2023, helmed by Professor Andrea Maier. The UK is running the 1M Phenome Initiative, led by Leroy Hood, Adil Mardinoglu, and Mathias Uhlén at King’s College London. The goal is one million phonemes for longevity research. Abu Dhabi’s Department of Health licensed the world’s first regulated Healthy Longevity Medicine Centre in November 2024, with formal facility standards effective from April 2025.
Why longevity medicine is emerging right now
Three forces converged in the last five years to make this field clinically and operationally viable.
Infrastructure crossed a line. The diagnostic tools at the centre of longevity medicine moved from research-only into clinical price points. Epigenetic clock measurement, historically a methylation array costing hundreds of dollars per sample, dropped roughly 100-fold with the TIME-seq method published in Nature Aging in 2024. The new method produces a clinically usable human blood clock with a median error of 3.39 years at approximately $6 per sample. Whole-body MRI screening followed a similar trajectory. Prenuvo charged around $2,500 in 2024. After Function Health acquired Ezra in 2025, the same category of scan launched at $499.
Demand shifted in parallel. The 9.6-year healthspan-lifespan gap from the opening is the headline statistic, but the underlying experience is more visible than that number suggests. Most middle-aged adults have direct experience watching parents or older relatives spend years in measurable decline before death.
Healthspan is no longer an abstract category. It is felt.
2025 marked a clear inflection point for longevity medicine. Not because of a single breakthrough. But because infrastructure, demand, and global participation finally aligned. The conversation shifted from what’s possible to what actually works at scale.
—Samir Mitra, Founder and CEO, Reya.ai. (Source: Samir Mitra LinkedIn, April 2026.)
Global participation broadened the field. Longevity medicine is no longer a Western export. Singapore institutionalised it inside a public hospital. The UK is gathering biomarker data at population scale through the 1M-PI initiative. Asia-Pacific growth rates exceed every other region. Biological age testing is now offered in regional hubs across the Gulf, Southeast Asia, and Latin America.
The science behind longevity and preventive care has been clear for a long time. The evidence was there. The protocols were there. What was missing was the infrastructure to support it. Over the last several years, we have been building in that gap, turning what was once largely theoretical into a system clinics can actually implement in day-to-day care.
—Samir Mitra, Founder and CEO, Reya.ai. (Source: Samir Mitra LinkedIn, on Reya.ai’s Outstanding Organization Award at Health 2.0.)
The convergence is the point. Each force alone would not produce a new clinical specialty. All three together are why longevity medicine is consolidating now and not in 2010 or 2030.
What a longevity medicine consultation actually looks like
Your first visit at a longevity clinic does not look like your first visit at a primary care practice. The structure is different by design.
Pre-visit intake usually starts 7 to 14 days before you arrive. You complete a detailed questionnaire covering full medical history, family history across three generations, lifestyle data on sleep and exercise, dietary patterns, stress and mental health history, and current supplement and medication use. Some clinics ask you to mail in a finger-prick blood sample for an epigenetic biological age test before your visit, so the results are available when you sit down with the physician.
The diagnostic workup at the visit itself is more comprehensive than a standard executive physical. Biological age testing comes first, typically through an epigenetic clock such as DunedinPACE or GrimAge. The lab work extends well beyond a standard CBC, including ApoB and Lp(a) for cardiovascular risk, a full hormone profile, and inflammation markers.
The functional and imaging tests include a DEXA scan for body composition and bone density, a VO₂ max test under cardiopulmonary stress, and increasingly, a whole-body MRI for structural screening. Many clinics also send you home with a continuous glucose monitor for two weeks. Total time at the clinic is typically a half day to a full day. Over the first three weeks, total time including intake, testing, and review is closer to ten hours.
The physician review session is where the work happens. What does a longevity doctor do during a review? They synthesise the entire dataset, identify the three to five most actionable signals, and walk you through what each one means in the context of your full picture. A high biological age relative to chronological age, for example, is interpreted alongside your inflammation markers, sleep data, fitness, and family history rather than as a standalone number.
Protocol design is the output. You leave with a written longitudinal plan covering lifestyle changes, any indicated supplementation, exercise prescription, sleep and stress protocols, and a follow-up testing cadence. Most clinics retest changeable biomarkers every six months and biological age annually.
Longitudinal follow-up between visits is what separates serious longevity medicine from one-off executive screenings. It is also where most of the operational complexity lives, which is why software has become central to the field.
The future of longevity medicine
Three near-term directions are visible.
Agentic AI is moving into continuous biomarker interpretation. A 2025 review in Aging synthesised 125 peer-reviewed studies on deep learning and generative AI in aging research. The review concluded that AI systems are now central to biomarker discovery, deep aging clock development, and clinical decision support in longevity medicine. The bottleneck is no longer data acquisition. It is moving from raw data to clinical action at the speed and scale a real practice requires.
This is where the operational architecture shifts from theoretical to functional. For example, rather than requiring patients to manually log meals, a workflow notorious for low compliance, Reya’s platform deploys a specialized AI Agent for food journaling. Members simply take photos of their meals to get automated, precise breakdowns of macronutrients.
Crucially, Reya’s correlation tool then maps these meals directly against continuous data streams from wearables. By cross-referencing a photo-logged meal with a patient’s subsequent physiological responses, the system uncovers hidden biological insights, such as specific foods driving glycemic spikes or disrupting nocturnal recovery that a standard clinic physically would entirely miss.
Cost democratisation is the second direction. As diagnostic costs continue to fall (the epigenetic clock trajectory from hundreds of dollars to $6 per sample is the cleanest example), the clinical model that depends on premium membership pricing will face pressure. Either prices come down or the field bifurcates into a high-end concierge tier and a mass-market preventive tier. Both outcomes are likely.
The evidence base is maturing.
Senolytics, drugs that selectively remove senescent cells, are still in research and early clinical trials. Partial epigenetic reprogramming using Yamanaka factors is producing striking results in animal models but is years from clinical practice. mTOR inhibition via rapamycin is being studied off-label, with the PEARL trial completed in 2023. None of these are mainstream longevity specialty practices yet. All three are likely to be in five years.
The clarity of the longevity medicine definition matters more as the category scales than it did when the category was small. Five years ago, mislabeling was a marketing problem. With more than 700 clinics today, regulatory bodies starting to draft facility standards, and millions of consumers researching the field, mislabeling is a clinical problem.
A patient who walks into a “longevity clinic” expecting biomarker-driven preventive care and receives cosmetic procedures has been mis-sold. A clinician practicing serious longevity medicine alongside practices selling supplement protocols under the same banner has a credibility problem they did not create.
Serious preventive medicine cannot run on sick-care architecture. The science of longevity medicine is already here. The bottleneck is the clinical workflow. Reya provides the operational infrastructure that turns continuous biomarker tracking into scalable clinical practice.
Frequently Asked Questions
Longevity medicine is governed by a non-profit international society (the Healthy Longevity Medicine Society, founded 2022), credentialed through ABAARM and A4M’s Fellowship in Longevity Medicine, and now regulated under government licensing frameworks. The legitimacy question persists because supplement marketing and self-experimentation projects borrow the same vocabulary. Physician-led longevity medicine, with proper credentials and clinical infrastructure, is a serious clinical specialty distinct from those adjacent activities.
Primary care doctors can transition into the field, but it requires significant additional training. Standard medical education focuses heavily on diagnosing and treating acute or advanced chronic disease. Practicing preventive longevity care requires upskilling in molecular biology, advanced biomarker interpretation, and the application of clinical frameworks designed to optimise healthspan rather than manage illness. Most physicians making the transition pursue ABAARM certification, the A4M Fellowship in Longevity Medicine, or the Longevity Medicine curriculum series.
Biological age testing (epigenetic clocks like DunedinPACE and GrimAge), multi-omics panels covering genomics, proteomics, metabolomics, and microbiome, advanced cardiovascular markers (ApoB, Lp(a), hs-CRP), VO₂ max under cardiopulmonary stress, DEXA scans for body composition and bone density, continuous glucose monitoring for non-diabetic patients, and increasingly, whole-body MRI screening. Most of these are validated diagnostics not routinely ordered in primary care because they do not map to insurance billing codes for asymptomatic patients.
No longevity medicine intervention has been proven to extend maximum human lifespan in a randomised controlled trial, because such trials would take decades to complete. What is established is that several validated interventions extend healthspan and reduce all-cause mortality. Exercise, sleep optimisation, blood pressure management, and metabolic health improvements all have strong evidence behind them. Longevity medicine integrates these into systematic, biomarker-guided protocols rather than treating them as separate lifestyle advice.
Most physicians in the field recommend starting between ages 35 and 45. Biomarker trends become detectable and modifiable during this window, and lifestyle changes implemented in the 40s have decades to compound. Earlier engagement is appropriate for people with strong family history of early-onset disease, known genetic variants, or specific risk factors. Late engagement (60+) is still valuable, but the intervention window narrows.
Artificial intelligence addresses the data bottleneck in modern longevity clinics. A single patient tracking wearables, continuous glucose monitors, and multi-omics panels generates substantial continuous data each month. Agentic AI systems monitor this data in the background, flag concerning biomarker drift, and highlight the specific data points that require human physician review. That work is what makes continuous care economically viable at the membership pricing most clinics operate on.
References
1. Bischof E, Scheibye-Knudsen M, Siow R, Moskalev A. Longevity medicine: upskilling the physicians of tomorrow. Lancet Healthy Longev. 2021;2(4):e187-e188. thelancet.com
2. Garmany A, Terzic A. Global Healthspan-Lifespan Gaps Among 183 World Health Organization Member States. JAMA Netw Open. 2024;7(12):e2450241. PMC11635540
3. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243-278. PubMed 36599349
4. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol. 2011;8:184-187. nature.com
5. Griffin PT, Kane AE, Trapp A, et al. TIME-seq reduces time and cost of DNA methylation measurement for epigenetic clock construction. Nat Aging. 2024;4(2):261-274. PubMed 38200273
6. Wilczok D. Deep learning and generative artificial intelligence in aging research and healthy longevity medicine. Aging (Albany NY). 2025. aging-us.com
7. The Business Research Company. Longevity Clinic Market Report 2026. researchandmarkets.com
8. Marketintelo. Longevity Clinic Service Market Research Report 2034. marketintelo.com
9. Mordor Intelligence. Longevity Market Share, Size & Growth Outlook to 2031. mordorintelligence.com
10. Grand View Research. Anti-Aging Products Market Size, Industry Report 2033. grandviewresearch.com
11. Healthy Longevity Medicine Society. hlms.co
12. American Academy of Anti-Aging Medicine, ABAARM Board Certification. a4m.com